本报讯 （记者向炎涛）8月26日晚，北京中关村科技发展（控股）股份有限公司（以下简称"中关村"） 发布2025年半年度报告。上半年，公司实现营业收入12.39亿元，较上年同期基本持平；实现归属于上 市公司股东的净利润3880.89万元，同比增长6.65%；实现归属于上市公司股东的扣除非经常性损益的净 利润3685.49万元，同比增长36.34%。 报告期内，公司继续聚焦主业，推动精细化管理迈向更高阶段。同时，公司坚持内外结合，充分利用外 部资源，完善、丰富产品线，保持投入，夯实未来发展基础。 生物医药及健康品业务方面，公司药品生产和研发工作取得积极进展。报告期内，公司旗下北京华素收 到北京市药品监督管理局下发的《药品生产许可证》，生产范围增加原料药联苯苄唑，有利于公司优化 生产结构，丰富公司产品布局，满足市场需求。 药品销售工作方面，北京华素主要产品富马酸比索洛尔片（商品名：博苏）销量与上年同期基本持平， 核心产品盐酸贝尼地平片（注册商标：元治®）较上年同期继续保持增长；同时，战略产品"盐酸羟考 酮注射液"营业收入较上年同期增长逾90%。报告期内，"盐酸纳洛酮注射液"成功中选第十批国家组织 药品集中采购。 作 ...

Group 1: Company Strategy and Resource Allocation - The company focuses on the pharmaceutical health sector and plans to divest non-pharmaceutical assets to optimize its resource allocation over the next 3 to 5 years [2] - The company will carefully consider market trends and the status of existing assets before making decisions on asset optimization [2] Group 2: Product Performance and Market Trends - The core product, Benidipine Hydrochloride Tablets (trademark: Yuanzhi®), saw a nearly 29% increase in revenue in 2024 compared to the previous year [2] - The market share of Yuanzhi reached 55.57% in 2024, driven by an aging population and increasing hypertension cases [3] Group 3: Sales and Marketing Strategies - The company implemented a "three-full strategy" to expand its market presence and mitigate the impact of potential centralized procurement [2] - Sales expenses increased to 44.22% in Q1 2025 from 35.75% in 2024, attributed to heightened marketing efforts to ensure strong performance [7] Group 4: Future Growth and Product Development - The company anticipates a sales revenue increase of over 100% for Oxycodone Injection in 2025, supported by expanding usage in various medical fields [5] - The company is developing new products, including Methylphenidate Hydrochloride sustained-release tablets, with significant market potential in ADHD treatment [6] Group 5: Financial Projections - The company projects a revenue of 2.943 billion yuan and a net profit of 89 million yuan for 2025 [10] - In Q1 2025, the company achieved a revenue of 616 million yuan, a 1.63% increase year-on-year, and a net profit of 15.76 million yuan, up 35.47% from the previous year [10] Group 6: Digital Transformation and E-commerce - The company is advancing digital initiatives, including the establishment of digital workshops and exploring online sales channels [7] - The health product segment is focusing on expanding its product range and enhancing e-commerce operations to meet diverse consumer needs [8]